48
LATEST NEWS: 11 JUNE 2025
New findings from a trial into treating a common form of skin cancer – cutaneous squamous cell carcinoma (CSCC) – could be a game-changer for many people at high risk of recurrence of disease.
Lead investigator Prof Danny Rischin presented results of primary analysis of the C-POST trial at the ASCO (American Society of Clinical Oncology) meeting in Chicago, USA, in late May, as the findings were published in the New England Journal of Medicine.
The Phase III C-POST trial was sponsored by Regeneron…